Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Patent
1995-06-07
1999-01-26
Smith, Lynette F.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
435 71, 435 72, 530324, 530325, 530329, 530326, 530330, 514 15, 4242081, C12Q 170, G01N 3353, A61K 3804, C07K 500
Patent
active
058637184
ABSTRACT:
Short peptide of the formula:
REFERENCES:
patent: 4073885 (1978-02-01), Pert et al.
patent: 4371463 (1983-02-01), Pert et al.
patent: 4520113 (1985-05-01), Callo et al.
patent: 4525300 (1985-06-01), Yoshida et al.
patent: 4629783 (1986-12-01), Cosand
patent: 4737487 (1988-04-01), Watts et al.
patent: 4775759 (1988-10-01), Rice et al.
patent: 4956273 (1990-09-01), Kennedy et al.
patent: 5276016 (1994-01-01), Pert et al.
patent: 5529983 (1996-06-01), Pert et al.
Wetterberg, et al, 1987, "Peptide T in the treatment of AIDS". The Lancet, Jan. 17, 1987, p. 159.
The Lancet, Jan. 17, 1987, Hepatotoxicity of Cyclosporin in a Patient Given Nordette.
The Lancet, Boston Mass. and London Saturday Jul. 22, 1989 vol. II for 1989.
MacFadden, D.K.*, Doob, Penelope Reed *.** Role of Peptide T in Palliation of HIV-1-Related Painful Peripheral Neuropathy.
Douglass E. Brenneman, et al., Acquired Immune Deficiency Syndrome and the Developing Nervous System.
Phase I Studies of Peptide T for the Neuropsychiatric Complications of HIV Infection, Immunology Virology Pharmacokinetics.
Investigator's Brochure, D-Ala l-Peptide-T-Amide, (Peptide T) Integra Institute, Bethesda, Maryland.
I. Julander, et al., Treatment of HIV-1 Infected Patients with Peptide T. Published Jan. 1991.
Abstracts of Peptide T Clinical Results, Vth International Conference on AIDS, Montreal Jun. 4-9, 1989.
Manuscripts Concerning Peptide T Clinical Results Submitted and in Press. Michael R. Ruff et al., Pharmacokinetics of Peptide T in Patients with Acquired Immunodeficiency Syndrome (AIDS).
Kenneth Mayer, M.D., et al., A Phase I Study of Intranasal Peptide T for the Treatment of Symptomatic HIV-Infected Patients: Clinical and Laboratory Results. Running Head: Intranasal Peptide T in HIV Infection.
Jeanine Buzy, et al., Potent Neurotoxic Activity in the Cerebrospinal Fluid of HIV-Infected Individuals.
T. Peter Bridge, M.D. et al., Neuropsychiatric Outcome in HIV Dementia to Peptide T.
T. Peter Bridge, M.D. et al., Results of Extended Peptide T Administration in Aids and ARC Patients.
Marc. I. Rosen, et al., Peptide T Treatment of Cognitive Impairment In HIV+ Intravenous Drug Uners.
Peter Bridge, M.D. et al.,Neuropsychologic Results of Controlled Trial of Peptide T in HIV-1.
Virology Report. Pharmacology of Peptide T inhibition of in vitro HIV infection.
Peptide T Clinical Reports. Clinical Summary A Phase I Trial of Intranasal Peptide T: Safety, Toxicity and Pharmacokinetics in Human Immunodeficiency Virus 1 (HIV-1) Infected Patents.
Appendix I: Preliminary studies.
Appendex II. Neuropsychological Assessment.
AZT, AZT Placebo, and Peptide T, Neuropsychologic Test Z Scores AIDS and ARC Patients.
Fenway Clinic Trail EEG Report.
Peptide T Clinical Trials 1987-1988, NIMH/USC, Los Angeles.
Peptide T Clinical Trials 1986-1987, Karolinska Institute.
Neuropsychologic Testing Results Fenway Community Health Center Phase One Study Peptide T, IND. BB-2535 29 Oct. 9.
Angus G. Dalgleish et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature, vol. 312, 20/27, Dec. 1984.
Bruno R. Starcich, et al. Identification and Characterization of Conserved and Variable Regions in the Envelope Gene of HTLV-III/LAV, the Retrovirus of AIDS.
Ratner, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III.
Ray Sanchez-Pescador et al. Nucleotide Sequence and Expression of an AID-Associated Retrovirus (ARV-2), Science, vol. 227: pp. 484-492 (1985).
Candace B. Pert, Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity, Proc. Natl. Acad. Sci. USA, vol. 83, pp. 9254-9258, Dec. 1986.
J. A. Parsons, Biological Council, The Co-ordinating Committee for Symposia on Drug Action, Peptide Hormones, Jun. 1976.
Anthony S. Fauci, Current Issues in Developing a Strategy for Dealing with the Acquired Immunodefiency Syndrome, Proc. Natl. Acad. Sci. USA, vol. 83, pp. 9278-9283, Dec. 1986.
Edward S. Golub, The Cellular Basis of the Immune Response, an approach to Immunobiology. Sinaurer Associates, Inc., Sunderland, MA.
Donald J. Cram, Organic Chemistry. McGraw-Hill Book Company, 1964.
Albert L. Lehninger, Principles of Biochemistry. The Johns Hopkins University, School of Medicine, Worth Publishers, Inc. 1982.
The Spectrum of Disease due to Human Immunodeficiency Virus, by Donna Mildvan, Current Topics in AIDS, vol. 1., pp. 31-45, 1987.
Human Immunodeficiency Virus and Related Viruses, by Myra O. McClure and Robin A. Weiss, Current Topics in AIDS, vol. 1, pp. 95-117, 1987.
Michael R. Ruff et al. CD4 Receptor binding peptides that block HIV Infectivity cause human monocyte chemotaxis, FEB Letters, vol. 211, No. 1, pp. 17-22. Jan. 1987.
Farrar William L.
Pert Candance B.
Ruff Michael R.
Smith Lynette F.
The United States of America as represented by the Department of
LandOfFree
Small peptides which inhibit to T-4 receptors and act as immunog does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Small peptides which inhibit to T-4 receptors and act as immunog, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Small peptides which inhibit to T-4 receptors and act as immunog will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1449423